Loading...
0

Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) and Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

LI_183612
Pages: 166
Jul 2019 | 2466 Views
 
Author(s) : Tenzin Kunsel , Onkar Sumant
Tables: 80
Charts: 34
 

Narcolepsy Drugs Market Outlook - 2026

The global narcolepsy drugs market size was around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026. Narcolepsy is a long-term neurological disorder, which involves a decreased ability to regulate sleep–wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes, and can occur at any time. Around 70% of people experience episodes of sudden loss of muscle strength, known as cataplexy, which can also known to strongly affect the emotional state of patients. Less commonly, there may be inability to move or vivid hallucinations when falling asleep or waking up. People suffering from narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

Narcolepsy Drugs Market

Get more information on this report : Request Sample Pages

The low prevalence rate of narcolepsy makes it an orphan disease. However, the importance of narcolepsy drugs is not affected by the low prevalence rate, as the symptoms such as cataplexy can be life-threatening for patients suffering from narcolepsy. In addition, stressful lifestyle and increase in consumption of alcohol, tobacco, and coffee are expected to increase the risk of narcolepsy. Moreover, high disposable income and increase in awareness about the benefits of narcolepsy drugs are anticipated to fuel the market growth globally.

Narcolepsy is a rare and underdiagnosed chronic condition, thus there are many undiagnosed patients worldwide. Increase in severity of the disease and rise in number of people being affected by narcolepsy are the key factors that drive the narcolepsy drugs market growth. Moreover, narcolepsy drugs can also be used in sleep apnea treatment. Furthermore, the availability of reimbursement process for FDA-approved prescription medicines boosts the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability is expected to hinder the market growth. On the contrary, increase in the number of programs organized by various organizations to spread awareness is anticipated to provide lucrative opportunities for the market growth.

Narcolepsy Drugs Market by Disease Type

Get more information on this report : Request Sample Pages

Disease type segment review

Based on disease type, the narcolepsy drugs market is segmented into daytime extreme sleepiness, cataplexia, and others. Excessive daytime sleepiness is one of the most common sleep-related symptoms, and it affects an estimated 20% of the population. The daytime extreme sleepiness segment is the highest revenue generator in the overall narcolepsy drugs market, as rise in prevalence of narcolepsy and other sleep disorders increase the risk of this symptom, thereby boosting the demand for narcolepsy drugs. Cataplexia is the sudden loss of muscle tone, while a person is awake, and leads to weakness and loss of voluntary muscle control. However, the cataplexia segment is expected to grow at the highest rate, as patients suffering from cataplexia tend to lose muscle control, and almost 70% of narcolepsy patients are found to have this symptom.

Narcolepsy Drugs Market by Therapeutics Type

Get more information on this report : Request Sample Pages

Therapeutics type segment review

Based on therapeutics type, the narcolepsy drugs market is segmented into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Sodium oxybate, also known as gamma-hydroxybutyrate or GHB, is approved by the FDA to treat cataplexy and excessive daytime sleepiness (EDS). Sodium oxybate holds the highest global narcolepsy drugs market share, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. Selective serotonin reuptake inhibitors (SSRIs) are useful in treating cataplexy at doses that are comparable to those used to treat depression. However, selective serotonin reuptake inhibitor segment is expected to grow at the highest rate due to increase in R&D activities for the development of these type of drugs by the key players.

Narcolepsy Drugs Market by Geography

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the narcolepsy drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the major segment in the global narcolepsy drugs market, and is anticipated to remain dominant during the forecast period. This is attributed to rise in number of narcolepsy and other sleep disorder cases in North America. As per the statistics by the American Academy of Sleep Medicine, almost 1 in approximately 2,000 people in the U.S. suffer from narcolepsy. However, Asia-Pacific is anticipated to grow at the highest rate in the narcolepsy drugs market, due to increase in prevalence of narcolepsy and rise in adoption rate of narcolepsy drugs.

The report provides a comprehensive analysis of the key players operating in the global narcolepsy drugs market. These players include Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. Furthermore, numerous companies are introducing advanced narcolepsy drugs that will help to treat symptoms associated with narcolepsy and other sleep disorders and improve the quality of sleep.

Key Benefits for Narcolepsy Drugs Market:

  • This report provides a detailed quantitative analysis of the current narcolepsy drugs market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global narcolepsy drugs market is provided.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

Narcolepsy Drugs Key Market Segments:

By Disease Type

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others

By Therapeutics Type

  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Sodium Oxybate
  • Selective Serotonin Reuptake Inhibitor
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market Definition and Scope
3.2.    Parent Market Overview
3.3.    Key Forces Shaping Narcolepsy Drugs Market

3.3.1.    Moderate bargaining power of suppliers
3.3.2.    Low bargaining power of buyers
3.3.3.    Low threat of new entrants
3.3.4.    Moderate threat of substitutes
3.3.5.    Moderate intensity of rivalry

3.4.    Pricing Analysis

3.4.1.    Pricing Analysis, By Region, 2018 & 2025

3.5.    Market Evolution
3.6.    Value Chain Analysis
3.7.    Impact of government regulations on global narcolepsy drugs market
3.8.    Patent Analysis

3.8.1.    By Region
3.8.2.    By Applicant

3.9.    Market Dynamics

3.9.1.    Drivers

3.9.1.1.    Increase in global prevalence of narcolepsy
3.9.1.2.    Narcolepsy awareness programs and services
3.9.1.3.    Presence of reimbursement policies regarding narcolepsy

3.9.2.    Restraints

3.9.2.1.    Adverse effects and risks related to narcolepsy drugs
3.9.2.2.    Delayed diagnosis or misdiagnosis

3.9.3.    Opportunity

3.9.3.1.    Untapped markets in the developing countries

CHAPTER 4:    NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Daytime Extreme Sleepiness

4.2.1.    Key market trends and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Cataplexia

4.3.1.    Key market trends and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

4.4.    Other Disease Type

4.4.1.    Key market trends and opportunities
4.4.2.    Market size and forecast
4.4.3.    Market analysis, by country

CHAPTER 5:    NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Central Nervous System Stimulants

5.2.1.    Market size and forecast
5.2.2.    Market analysis, by country

5.3.    Tricyclic Antidepressants

5.3.1.    Market size and forecast
5.3.2.    Market analysis, by country

5.4.    Sodium Oxybate

5.4.1.    Market size and forecast
5.4.2.    Market analysis, by country

5.5.    Selective Serotonin Reuptake Inhibitor

5.5.1.    Market size and forecast
5.5.2.    Market analysis, by country

5.6.    Other Therapeutic Type

5.6.1.    Market size and forecast
5.6.2.    Market analysis, by country

CHAPTER 6:    NARCOLEPSY DRUGS MARKET, BY REGION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    North America

6.2.1.    Key market trends and opportunities
6.2.2.    North America market size and forecast, by disease type
6.2.3.    North America market size and forecast, by therapeutic type
6.2.4.    North America market size and forecast, by country

6.2.4.1.    U.S. market size and forecast, by disease type
6.2.4.2.    U.S. market size and forecast, by therapeutic type
6.2.4.3.    Canada market size and forecast, by disease type
6.2.4.4.    Canada market size and forecast, by therapeutic type
6.2.4.5.    Mexico market size and forecast, by disease type
6.2.4.6.    Mexico market size and forecast, by therapeutic type

6.3.    Europe

6.3.1.    Key market trends and opportunities
6.3.2.    Europe market size and forecast, by disease type
6.3.3.    Europe market size and forecast, by therapeutic type
6.3.4.    Europe market size and forecast, by country

6.3.4.1.    Germany market size and forecast, by disease type
6.3.4.2.    Germany market size and forecast, by therapeutic type
6.3.4.3.    France market size and forecast, by disease type
6.3.4.4.    France market size and forecast, by therapeutic type
6.3.4.5.    UK market size and forecast, by disease type
6.3.4.6.    UK market size and forecast, by therapeutic type
6.3.4.7.    Italy market size and forecast, by disease type
6.3.4.8.    Italy market size and forecast, by therapeutic type
6.3.4.9.    Spain market size and forecast, by disease type
6.3.4.10.    Spain market size and forecast, by therapeutic type
6.3.4.11.    Rest of Europe market size and forecast, by disease type
6.3.4.12.    Rest of Europe market size and forecast, by therapeutic type

6.4.    Asia-Pacific

6.4.1.    Key market trends and opportunities
6.4.2.    Asia-Pacific market size and forecast, by disease type
6.4.3.    Asia-Pacific market size and forecast, by therapeutic type
6.4.4.    Asia-Pacific market size and forecast, by country

6.4.4.1.    Japan market size and forecast, by disease type
6.4.4.2.    Japan market size and forecast, by therapeutic type
6.4.4.3.    China market size and forecast, by disease type
6.4.4.4.    China market size and forecast, by therapeutic type
6.4.4.5.    Australia market size and forecast, by disease type
6.4.4.6.    Australia market size and forecast, by therapeutic type
6.4.4.7.    India market size and forecast, by disease type
6.4.4.8.    India market size and forecast, by therapeutic type
6.4.4.9.    South Korea market size and forecast, by disease type
6.4.4.10.    South Korea market size and forecast, by therapeutic type
6.4.4.11.    Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.12.    Rest of Asia-Pacific market size and forecast, by therapeutic type

6.5.    LAMEA

6.5.1.    Key market trends and opportunities
6.5.2.    LAMEA market size and forecast, by disease type
6.5.3.    LAMEA market size and forecast, by therapeutic type
6.5.4.    LAMEA market size and forecast, by country

6.5.4.1.    Brazil market size and forecast, by disease type
6.5.4.2.    Brazil market size and forecast, by therapeutic type
6.5.4.3.    Saudi market size and forecast, by disease type
6.5.4.4.    Saudi market size and forecast, by therapeutic type
6.5.4.5.    South Africa market size and forecast, by disease type
6.5.4.6.    South Africa market size and forecast, by therapeutic type
6.5.4.7.    Rest of LAMEA market size and forecast, by disease type
6.5.4.8.    Rest of LAMEA market size and forecast, by therapeutic type

CHAPTER 7:    COMPETITIVE LANDSCAPE

7.1.    Introduction
7.2.    Market Share Analysis of Top Players, 2018 (%)
7.3.    Product Mapping of Top Players
7.4.    Competitive Heatmap

CHAPTER 8:    COMPANY PROFILES

8.1.    ARENA PHARMACEUTICAL, INC.

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Business performance

8.2.    BIOPROJET PHARMA SARL

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments

8.3.    JAZZ PHARMACEUTICAL PLC

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Operating segments
8.3.5.    Business Performance
8.3.6.    Key strategic moves and developments

8.4.    LIGAND PHARMACEUTICALS INCORPORATED

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Operating business segments
8.4.4.    Business performance

8.5.    NOVARTIS INTERNATIONAL AG

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Business performance

8.6.    SHINOGI INC.

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Product portfolio
8.6.5.    Business performance

8.7.    TAKEDA PHARMACEUTICAL COMPANY

8.7.1.    Company overview
8.7.2.    Company snapshot
8.7.3.    Operating business segments
8.7.4.    Business performance

8.8.    TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.8.1.    Company overview
8.8.2.    Company snapshot
8.8.3.    Operating business segments
8.8.4.    Product portfolio
8.8.5.    Business performance

LIST OF TABLES

TABLE 01.    GLOBAL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026 ($MILLION)
TABLE 02.    NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2018–2026 ($MILLION)
TABLE 03.    NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, 2018–2026 ($MILLION)
TABLE 04.    NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2018–2026 ($MILLION)
TABLE 05.    GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 06.    NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 07.    NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 08.    NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY REGION, 2018–2026, ($MILLION)
TABLE 09.    NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018–2026, ($MILLION)
TABLE 10.    NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2018–2026, ($MILLION)
TABLE 11.    NARCOLEPSY DRUGS MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 12.    NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 13.    NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 14.    NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 15.    U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 16.    U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 17.    CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 18.    CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 19.    MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 20.    MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 21.    EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 22.    EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 23.    EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 24.    GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 25.    GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 26.    FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 27.    FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 28.    UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 29.    UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 30.    ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 31.    ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 32.    SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 33.    SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 34.    REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 35.    REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 36.    ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 37.    ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 38.    ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 39.    JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 40.    JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 41.    CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 42.    CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 43.    AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 44.    AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 45.    INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 46.    INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 47.    SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 48.    SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 49.    REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 50.    REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 51.    LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 52.    LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 53.    LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 54.    BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 55.    BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 56.    SAUDI NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 57.    SAUDI NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 58.    SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 59.    SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 60.    REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 61.    REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 62.    ARENA: COMPANY SNAPSHOT
TABLE 63.    ARENA: OPERATING SEGMENTS
TABLE 64.    BIOPROJET PHARMA: COMPANY SNAPSHOT
TABLE 65.    BIOPROJET: OPERATING BUSINESS SEGMENTS
TABLE 66.    JAZZ: COMPANY SNAPSHOT
TABLE 67.    JAZZ: OPERATING SEGMENTS
TABLE 68.    JAZZ: OPERATING SEGMENTS
TABLE 69.    LIGAND PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 70.    LIGAND PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 71.    NOVARTIS AG: COMPANY SNAPSHOT
TABLE 72.    NOVARTIS: OPERATING SEGMENTS
TABLE 73.    SHIONOGI: COMPANY SNAPSHOT
TABLE 74.    SHIONOGI: OPERATING SEGMENTS
TABLE 75.    SHIONOGI: PRODUCT PORTFOLIO
TABLE 76.    TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 77.    TAKEDA PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 78.    TEVA: COMPANY SNAPSHOT
TABLE 79.    TEVA: OPERATING SEGMENTS
TABLE 80.    TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    PARENT MARKET
FIGURE 02.    MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03.    LOW BARGAINING POWER OF BUYERS
FIGURE 04.    LOW THREAT OF NEW ENTRANTS
FIGURE 05.    MODERATE THREAT OF SUBSTITUTES
FIGURE 06.    MODERATE INTENSITY OF RIVALRY
FIGURE 07.    PRICING ANALYSIS, BY REGION, 2018 & 2025
FIGURE 08.    VALUE CHAIN ANALYSIS
FIGURE 09.    PATENT ANALYSIS, BY REGION, (2014-2018)
FIGURE 10.    PATENT ANALYSIS, BY APPLICANT, (2014-2018)
FIGURE 11.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18.    COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19.    MARKET SHARE ANALYSIS: NARCOLEPSY DRUGS MARKET, 2018 (%)
FIGURE 20.    PRODUCT MAPPING OF TOP PLAYERS
FIGURE 21.    COMPETITIVE HEATMAP
FIGURE 22.    ARENA: NET SALES, 2016–2018 ($MILLION)
FIGURE 23.    JAZZ: NET SALES, 2016-2018 ($MILLION)
FIGURE 24.    JAZZ: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25.    LIGAND PHARMACEUTICAL: NET SALES, 2016–2018 ($MILLION)
FIGURE 26.    NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.    NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29.    SHIONOGI: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.    SHIONOGI: BY REGION, 2018 (%)
FIGURE 31.    TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 32.    TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33.    TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 34.    TEVA: REVENUE SHARE BY REGION, 2018 (%)

 
 

Although narcolepsy is considered an orphan disease, narcolepsy drugs are gaining popularity due to rise in awareness regarding the availability of these drugs that are most commonly used to treat extreme daytime sleepiness and cataplexy. These drugs help improve the quality of sleep of the patient and the overall patient lifestyle. Moreover, they help in the treatment of similar symptoms that patients are suffering from other types of sleep disorders such as insomnia.

The selective serotonin reuptake inhibitor segment registered the highest growth rate in 2018, and is anticipated to provide lucrative opportunities for the market players. Increase in R&D activities has been witnessed for the development of these drugs to reduce the side effects of these drug.

North America leads the global narcolepsy drugs market, owing to rise in awareness regarding narcolepsy solutions. Asia-Pacific is growing at the fastest CAGR due to increase in disposable income and rise in affordability for advanced narcolepsy treatments.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Narcolepsy Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Narcolepsy Drugs Market"
Purchase Enquiry